UroGen Pharma (URGN) Long-Term Investments (2016 - 2026)

UroGen Pharma (URGN) has 11 years of Long-Term Investments data on file, last reported at $177000.0 in Q1 2026.

• Quarterly Long-Term Investments fell 96.08% year-over-year to $177000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $177000.0 (down 96.08% YoY) and the FY2025 annual result came in at $177000.0, down 96.48% from the prior year.
• Long-Term Investments was little changed at $177000.0 in Q1 2026, from $177000.0 in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $10.2 million in Q1 2023 to a low of $177000.0 in Q4 2025.
• A 5-year average of $3.0 million and a median of $674000.0 in 2022 frame the typical range for Long-Term Investments.
• Annual changes were most pronounced in 2023 — Long-Term Investments jumped 2817.94% — and 2024, when it plunged 97.45%.
• Tracing URGN's Long-Term Investments over 5 years: stood at $223000.0 in 2022, then jumped by 1918.83% to $4.5 million in 2023, then climbed by 11.55% to $5.0 million in 2024, then plunged by 96.48% to $177000.0 in 2025, then changed by 0.0% to $177000.0 in 2026.
• The last three Long-Term Investments figures came in at $177000.0 (Q1 2026), $177000.0 (Q4 2025), and $380000.0 (Q3 2025), per Business Quant data.